These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32489505)

  • 1. Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice.
    Furubayashi N; Kuroiwa K; Tokuda N; Tomoda T; Morokuma F; Hori Y; Negishi T; Inoue T; Kumagai M; Nakamura M
    J Clin Med Res; 2020 May; 12(5):300-306. PubMed ID: 32489505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
    Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
    Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice.
    Tamura D; Jinnouchi N; Abe M; Ikarashi D; Matsuura T; Kato R; Maekawa S; Kato Y; Kanehira M; Takata R; Obara W
    Int J Clin Oncol; 2020 May; 25(5):899-905. PubMed ID: 31907720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study.
    Giannatempo P; Raggi D; Marandino L; Bandini M; Farè E; Calareso G; Colecchia M; Gallina A; Ross JS; Alessi A; Briganti A; Montorsi F; Madison R; Necchi A
    Ann Oncol; 2020 Dec; 31(12):1764-1772. PubMed ID: 32979512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
    Massari F; Santoni M; Takeshita H; Okada Y; Tapia JC; Basso U; Maruzzo M; Scagliarini S; Büttner T; Fornarini G; Myint ZW; Galli L; Souza VC; Pichler R; De Giorgi U; Gandur N; Lam ET; Gilbert D; Popovic L; Grande E; Mammone G; Berardi R; Crabb SJ; Kemp R; Molina-Cerrillo J; Freitas M; Luz M; Iacovelli R; Calabrò F; Tural D; Atzori F; Küronya Z; Chiari R; Campos S; Caffo O; Fay AP; Kucharz J; Zucali PA; Rinck JA; Zeppellini A; Bastos DA; Aurilio G; Mota A; Trindade K; Ortega C; Sade JP; Rizzo M; Fiala O; Vau N; Giannatempo P; Barillas A; Monteiro FSM; Dauster B; Mennitto A; Nogueira L; de Carvalho Fernandes R; Seront E; Aceituno LG; Grillone F; Cutuli HJ; Fernandez M; Bassanelli M; Kopp RM; Roviello G; Abahssain H; Procopio G; Milella M; Kopecky J; Martignetti A; Messina C; Caitano M; Inman E; Kanesvaran R; Herchhorn D; Santini D; Bamias A; Bisonni R; Mosca A; Morelli F; Maluf F; Soares A; Nunes F; Pinto A; Zgura A; Incorvaia L; Ansari J; Zabalza IO; Landmesser J; Rizzo A; Mollica V; Marchetti A; Rosellini M; Sorgentoni G; Battelli N; Buti S; Porta C; Bellmunt J
    Cancer Immunol Immunother; 2024 Apr; 73(6):106. PubMed ID: 38634928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study.
    Narita T; Hatakeyama S; Numakura K; Kobayashi M; Muto Y; Saito M; Narita S; Tanaka T; Noro D; Tokui N; Yoneyama T; Hashimoto Y; Habuchi T; Ohyama C
    Int J Urol; 2021 Sep; 28(9):899-905. PubMed ID: 34028105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
    Balar AV; Castellano DE; Grivas P; Vaughn DJ; Powles T; Vuky J; Fradet Y; Lee JL; Fong L; Vogelzang NJ; Climent MA; Necchi A; Petrylak DP; Plimack ER; Xu JZ; Imai K; Moreno BH; Bellmunt J; de Wit R; O'Donnell PH
    Ann Oncol; 2023 Mar; 34(3):289-299. PubMed ID: 36494006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma.
    Furubayashi N; Hori Y; Morokuma F; Tomoda T; Negishi T; Inoue T; Kumagai M; Kuroiwa K; Tokuda N; Nakamura M
    Mol Clin Oncol; 2021 May; 14(5):91. PubMed ID: 33767860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
    Fradet Y; Bellmunt J; Vaughn DJ; Lee JL; Fong L; Vogelzang NJ; Climent MA; Petrylak DP; Choueiri TK; Necchi A; Gerritsen W; Gurney H; Quinn DI; Culine S; Sternberg CN; Nam K; Frenkl TL; Perini RF; de Wit R; Bajorin DF
    Ann Oncol; 2019 Jun; 30(6):970-976. PubMed ID: 31050707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
    Bellmunt J; de Wit R; Vaughn DJ; Fradet Y; Lee JL; Fong L; Vogelzang NJ; Climent MA; Petrylak DP; Choueiri TK; Necchi A; Gerritsen W; Gurney H; Quinn DI; Culine S; Sternberg CN; Mai Y; Poehlein CH; Perini RF; Bajorin DF;
    N Engl J Med; 2017 Mar; 376(11):1015-1026. PubMed ID: 28212060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab.
    Sato R; Inamoto T; Matsushita Y; Takemura A; Uchimoto T; Sano A; Tanaka H; Ishikawa G; Watanabe K; Watanabe H; Tamura K; Motoyama D; Sugiyama T; Otsuka A; Harada KI; Azuma H; Miyake H
    Int J Urol; 2023 Sep; 30(9):730-736. PubMed ID: 36575640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Factors of Platinum-Refractory Advanced Urothelial Carcinoma Treated with Pembrolizumab.
    Akashi Y; Yamamoto Y; Hashimoto M; Adomi S; Fujita K; Kiba K; Minami T; Yoshimura K; Hirayama A; Uemura H
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
    Shindo T; Hashimoto K; Takahashi A; Miyamoto S; Kunishima Y; Sato S; Fukuta F; Hiyama Y; Takayanagi A; Kato R; Wanifuchi A; Ueki Y; Okada M; Adachi H; Kobayashi KO; Tanaka T; Masumori N;
    Anticancer Res; 2024 Mar; 44(3):1271-1279. PubMed ID: 38423657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
    Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
    Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407.
    Powell SF; Rodríguez-Abreu D; Langer CJ; Tafreshi A; Paz-Ares L; Kopp HG; Rodríguez-Cid J; Kowalski DM; Cheng Y; Kurata T; Awad MM; Lin J; Zhao B; Pietanza MC; Piperdi B; Garassino MC
    J Thorac Oncol; 2021 Nov; 16(11):1883-1892. PubMed ID: 34265431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial.
    de Wit R; Vaughn DJ; Fradet Y; Fong L; Climent MA; Necchi A; Petrylak DP; Gerritsen WR; Gurney H; Quinn DI; Culine S; Sternberg CN; Bajorin DF; Choueiri TK; Xu J; Imai K; Homet Moreno B; Bellmunt J; Lee JL
    Eur Urol; 2024 Aug; ():. PubMed ID: 39174409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study.
    Furubayashi N; Morokuma F; Tomoda T; Hori Y; Negishi T; Miura A; Komori H; Kuroiwa K; Nakamura M
    Anticancer Res; 2022 Mar; 42(3):1571-1577. PubMed ID: 35220254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project.
    Rizzo A; Monteiro FSM; Ürün Y; Massari F; Park SH; Bourlon MT; Poprach A; Rizzo M; Takeshita H; Giannatempo P; Soares A; Roviello G; Molina-Cerrillo J; Carrozza F; Abahssain H; Messina C; Kopp RM; Pichler R; Formisano L; Tural D; Atzori F; Calabrò F; Kanesvaran R; Buti S; Santoni M
    Target Oncol; 2024 Sep; 19(5):747-755. PubMed ID: 39107651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.